Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | HRH2 | P25021 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7744512 | 0.88 | OPRM1 (0.66) | OPRM1OPRL1ADRA2ADRD4SLC6A4 | |
| SCHEMBL6695001 | 0.87 | OPRM1 (0.65) | OPRM1OPRL1ADRA2ADRD4SLC6A4 | |
| SCHEMBL6841843 | 0.86 | OPRM1 (0.55) | OPRM1OPRL1ADRA2ADRD4SLC6A4 | |
| Hydrochloric Acid SCHEMBL7738855 | 0.86 | OPRM1 (0.64) | OPRM1OPRL1ADRA2ADRD4SLC6A4 | |
| SCHEMBL6664282 | 0.86 | OPRM1 (0.48) | OPRM1OPRL1ADRA2ADRD4SLC6A4 | |
| SCHEMBL7760719 | 0.82 | OPRM1 (0.47) | OPRM1OPRL1ADRA2ADRD4SLC6A4 | |
| SCHEMBL6665371 | 0.82 | OPRM1 (0.72) | OPRM1OPRL1ADRA2ADRD4SLC6A4 | |
| SCHEMBL6661642 | 0.82 | OPRM1 (0.72) | OPRM1OPRL1ADRA2ADRD4SLC6A4 | |
| SCHEMBL6667234 | 0.81 | OPRM1 (0.48) | OPRM1OPRL1ADRA2ADRD4SLC6A4 | |
| SCHEMBL6694942 | 0.81 | OPRM1 (0.65) | OPRM1OPRL1ADRA2ADRD4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1097924-B1 | 4-hydroxy-4-phenylpiperidine derivatives having opioid agonist activity and pharmaceuticals containing the same | SSP CO LTD (JP) | 2004-08-25 | — | — | EP | disclosed |
| US-20040034104-A1 | 2,2-Diphenylbutanamide derivatives and medicines containing the same | SSP CO., LTD. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1325912-A1 | 2,2-DIPHENYLBUTANAMIDE DERIVATIVES AND MEDICINES CONTAINING THE SAME | SSP Co., Ltd. (JP) | 2003-07-09 | — | — | EP | disclosed |
| US-6362203-B1 | ANALGESICS | SSP CO., LTD (JP) | 2002-03-26 | — | — | US | disclosed |
| EP-1097924-A1 | 4-hydroxy-4-phenylpiperidine derivatives having -opioid agonist activity and pharmaceuticals containing the same | SSP Co., Ltd. (JP) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034104-A1 | 2,2-Diphenylbutanamide derivatives and medicines containing the same | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885OPRL1 4/4885ADRA2A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.